Article review : The DEPEND Trial- A New Dawn for HPV-Negative Head and Neck Cancer Treatment
The DEPEND Trial: A New Dawn for HPV-Negative Head and Neck Cancer
Neoadjuvant Nivolumab, Response-Adapted Chemoradiation and the Future of Precision HNSCC Care
Article Citation
Rosenberg AJ, Juloori A, Jelinek MJ, et al. Neoadjuvant nivolumab plus chemotherapy followed by response‑stratified chemoradiation therapy in HPV‑negative head and neck cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncology. 2025;11(5):e250081. doi:10.1001/jamaoncol.2025.0081
Five Key Takeaways for Busy Clinicians
- Response‑adapted radiotherapy works: Deep responders (≥50% shrinkage) can receive 66 Gy with markedly less mucositis and xerostomia while maintaining early disease control.
- Chemo‑immunotherapy shows real activity: A 53% deep response rate and 73% 2‑year OS in HPV‑negative stage IVa/b HNSCC is notable in this poor‑risk population.
- Biomarkers will matter: PD‑L1 expression correlates with response and outcome, supporting future biomarker‑driven selection strategies.
- Evidence is promising, not definitive: Single‑arm, single‑centre phase 2 data need confirmation in randomised, multi‑centre trials before routine adoption.
- NHS implementation needs validation and infrastructure: Any move towards DEPEND‑like protocols will require NICE review, imaging capacity, and robust MDT processes.
Why the DEPEND Trial Matters
HPV‑negative head and neck squamous cell carcinoma (HNSCC) remains one of the most unforgiving cancers in clinical practice, with poorer outcomes and fewer effective options than its HPV‑positive counterpart. Conventional concurrent chemoradiation has plateaued in benefit, while toxicity continues to be substantial for many patients.
The DEPEND trial tests a different philosophy: use neoadjuvant chemo‑immunotherapy to identify patients with highly chemo‑sensitive, immunoresponsive disease, then dial down radiation dose only in those who respond deeply—aiming to protect function without sacrificing cure.
Study at a Glance
Design
Phase 2, single‑centre, nonrandomized trial (NCT03944915), HPV‑negative, stage IVa/b HNSCC.
Population
36 patients; median age ~59 years; predominantly male; all locoregionally advanced and non‑surgical.
Treatment Strategy
Neoadjuvant nivolumab plus carboplatin/paclitaxel → response‑stratified chemoradiation (66 Gy vs 70–75 Gy) → adjuvant nivolumab.
Primary Endpoint
Deep response rate (≥50% tumour shrinkage by RECIST 1.1 after neoadjuvant therapy).
The Numbers That Matter
The regimen delivers a meaningful signal of activity in a historically high‑risk population. Deep responses were common, overall responses were very high, and early survival outcomes compare favourably with historical chemotherapy‑based series.
Figure 1. Key Efficacy Endpoints from the DEPEND Trial
Deep response rate 53%, objective response rate 86%, and 2‑year overall survival 73% in HPV‑negative stage IVa/b HNSCC.
- Deep response rate: 53% (≥50% tumour shrinkage).
- Objective response rate: 86%.
- 2‑year progression‑free survival: ~66%.
- 2‑year overall survival: ~73%.
The De‑escalation Revolution: Less Radiation, Less Harm
The most innovative element of DEPEND is not the drugs themselves, but what happens after response assessment. Patients with deep responses (≥50% shrinkage) received de‑escalated radiotherapy to 66 Gy, while non‑deep responders received standard 70–75 Gy dosing.
This response‑adapted approach translated into visibly lower acute toxicity, particularly for mucositis, dermatitis and xerostomia—side effects that often define the lived experience of head and neck cancer treatment.
Figure 2. Acute Toxicity: De‑escalated vs Standard Radiation
Mucositis: 74% vs 94%; radiation dermatitis: 68% vs 88%; dry mouth: 37% vs 63% (de‑escalated vs standard radiation).
- Mucositis: 74% with de‑escalated dose vs 94% with standard dose.
- Radiation dermatitis: 68% vs 88%.
- Dry mouth: 37% vs 63%.
Study Design: The Good, the Bad, and the Real‑World
Methodologically, DEPEND is a well‑run phase 2 signal‑seeking study, but it is not definitive. The single‑arm, single‑centre design and modest sample size mean results should be seen as hypothesis‑generating rather than practice‑changing on their own.
The response‑stratified design, objective RECIST‑based assessment and prospectively planned biomarker work (PD‑L1) are major strengths. At the same time, the absence of a concurrent standard‑chemoradiation control arm and relatively immature survival data limit the ability to quantify how much nivolumab truly adds beyond optimised chemotherapy.
Clinical Relevance and NHS Implications
For UK practice, the DEPEND regimen is best viewed as an advanced‑centre strategy rather than an immediate new standard. It offers a compelling proof‑of‑concept that neoadjuvant chemo‑immunotherapy can safely enable radiation de‑escalation in good responders, with tangible reductions in acute toxicity.
Widespread NHS implementation would require NICE appraisal of nivolumab in this indication, investment in imaging and multidisciplinary workflow for timely response assessment, and validation in larger, preferably multi‑centre UK cohorts. Until then, DEPEND should inform trial design, MDT discussions, and patient counselling rather than wholesale protocol change.
Clinical Bottom Line
DEPEND is an important step towards genuinely personalised treatment for HPV‑negative head and neck cancer. It shows that with smart sequencing and careful response assessment, it may be possible to reduce radiation dose for selected patients without compromising outcomes. The next step is clear: scale this concept into multi‑centre randomised trials and, if confirmed, embed response‑adapted strategies into national pathways so that patients can benefit across the NHS, not just in specialist centres.
Published on DPS Oncology Blog | Evidence‑based commentary for practising oncologists
© 2025 Dr. [Your Name]. All rights reserved.
